Creative Destruction Lab (CDL) — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Axonis Therapeutics develops medicines targeting KCC2 to restore inhibition in the brain, with a focus on treating neurological disorders including epilepsy and pain.
BiotechMedical DevicesBoston, US
Shane Hegarty(Executive Officer)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Executive Officer, Director)
BoardCorey . Goodman(Director)Jonathan Leff(Director)Raymond J. Kelleher(Director)
Advanced ManufacturingToronto
Michael Christopher Floros(Executive Officer, Director, Promoter)Janaina Freitas Bortolatto(Executive Officer, Director, Promoter)Michael John O'Donoghue Tessier(Executive Officer, Director, Promoter)Kevin Weitzman(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.